Xerostomia Therapeutics MarketSize and Trends

Global Xerostomia Therapeutics Market: Dynamics

The major drivers of xerostomia therapeutics market include rising geriatric population and increasing incidence of medical conditions such as Sjögren disease, hypertension, Parkinson’s disease, cancer, HIV, diabetes, and others. For instance, the American College of Rheumatology reported that around 3.1 million people suffered from Sjogren's disorder in the U.S. in 2019. Moreover, the use of treatments such as chemotherapy and radiography for head or neck cancer treatment is expected to drive growth of xerostomia therapeutic market over the forecast period. Chemotherapy leads to damage of salivary gland cells and makes saliva thicker. However, this is a temporary side effect, which lasts for two-eight weeks post therapy. Radiotherapy related xerostomia lasts up to atleast six months post therapy. For instance, internal radiotherapy, external radiotherapy and systemic radiotherapy are widely used treatment methods for head and neck cancer.

Medicinal products such as toothpaste, mouthwash, lozenges, saliva substitute gels, and sugar-free chewing gums are easily available and inexpensive, hence driving the growth of the market. Furthermore, some expensive drugs such as Salagen, which are used as salivary stimulants for xerostomia treatment have favorable reimbursement policies. For instance, Ontario Ministry of Health and Long-Term Care provides funds to patients with radiation-induced xerostomia undergoing treatment with drug, Salagen, under the Exceptional Access Program (EAP). Furthermore, prescribed medicines such as antiparkinsonian, sedatives, antidepressants, and others cause xerostomia and its increasing usage is expected to drive the market growth. For instance, the National Institute of Dental and Craniofacial Research states that over 400 medications may cause xerostomia.